The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription
β Scribed by Fielding, S.L.; Flower, M.A.; Ackery, D.M.; Kemshead, J.; Lashfordd, L.S.; Lewis, I.J.
- Book ID
- 121954412
- Publisher
- Elsevier Science
- Year
- 1992
- Tongue
- English
- Weight
- 371 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0167-8140
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Between 7/3/80 and 5/7/86 we gave 32 of our neuroblastoma patients 62 diagnostic doses of metaiodobenzylguanidine (MIBG) and 12 patients 20 treatment doses. Our conclusion from our diagnostic dose studies is that MIBG should be used for staging the extent of neuroblastoma before therapy is started,
I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Becaus
Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow
From 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized neuroblastoma were treated with 131I-metaiodobenzylguanidine (mIBG) in several different treatment combinations. At initial diagnosis, 36 children had Evans stage IV and 11 stage III disease. In 16 of the 47 children, tumo